Big Pharma is rethinking the clinical trials process, establishing tighter links between clinical R&D and discovery. The buzzword is experimental medicine--a catchall for the set of tools and clinical strategies used to determine whether hitting a drug target modulates a disease process in a therapeutically useful way. By so doing, companies hope to reign in clinical costs--the bulk of drug development expenses--by avoiding massive drilling into what prove to be dry drug development holes. To some, experimental medicine is also a process to create a bridge between discovery research and clinical R&D--a large task given that they hold different mindsets.
By Mark L. Ratner
Over the past decade, spurred by the availability of genomics data, chemistry-oriented Big Pharma has acquired the toolkits of molecular...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.
